Invida to Market Breakthrough Anti-nausea Patch in Asia Pacific

Invida Pharmaceutical Holdings Pte Ltd, a specialty pharmaceutical company based in Singapore has signed an exclusive licence and supply agreement for Sancuso®, a patent-protected transdermal patch for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving chemotherapy for up to five consecutive days.

A world’s first, Sancuso® is a transdermal patch that delivers granisetron, an established 5HT3 receptor antagonist, steadily into the bloodstream for up to seven days, helping patients receiving a nausea-inducing chemotherapy regimen control their nausea and vomiting.

Sancuso® was approved in September 2008 by the US Food and Drug Administration (FDA) and launched in the US in November the same year by ProStrakan Group plc, an international specialty pharmaceutical company.

Under the terms of this exclusive license agreement, Invida Pharmaceutical Holdings Pte Ltd will purchase Sancuso® from ProStrakan and market the patch in several Asia Pacific countries, including Australia, Indonesia, the Philippines, Thailand and Vietnam. ProStrakan will receive undisclosed milestone payments, subject to the achievement of approval and sales targets.

“This marks a significant step in the development of our oncology portfolio across the Asia Pacific region,” said Invida’s Chief Executive Officer John Graham. “Sancuso® has the potential to significantly impact patient comfort and is exactly the type of novel treatment that will fulfill certain unmet medical needs in the region.”

Sancuso® has been proven to be as efficacious as oral granisetron in preventing the side effects of nausea and vomiting in patients undergoing chemotherapy, and also has the advantage of offering this protection through a single transdermal patch application. This eradicates the need to swallow multiple pills on a repeated basis and helps eliminate the need for repeated daily injections.